258 related articles for article (PubMed ID: 30219963)
41. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
[TBL] [Abstract][Full Text] [Related]
42. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
Gallamini A; Rigacci L; Merli F; Nassi L; Bosi A; Capodanno I; Luminari S; Vitolo U; Sancetta R; Iannitto E; Trentin L; Stelitano C; Tavera S; Biggi A; Castagnoli A; Versari A; Gregianin M; Pelosi E; Torchio P; Levis A
Haematologica; 2006 Apr; 91(4):475-81. PubMed ID: 16585014
[TBL] [Abstract][Full Text] [Related]
43. Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT.
Weiler-Sagie M; Kagna O; Dann EJ; Ben-Barak A; Israel O
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1133-40. PubMed ID: 24570095
[TBL] [Abstract][Full Text] [Related]
44. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
[TBL] [Abstract][Full Text] [Related]
45. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
46. The Effect of Interim FDG-PET-guided Response-Adapted Therapy in Pediatric Patients with Hodgkin's Lymphoma (HL-14) : Protocol for a Phase II Study.
Koga Y; Baba S; Fukano R; Nakamura K; Soejima T; Maeda N; Sunami S; Ueyama J; Mitsui T; Mori T; Osumi T; Sekimizu M; Ohki K; Tanaka F; Kamei M; Fujita N; Mori T; Saito AM; Kada A; Kobayashi R
Acta Med Okayama; 2018 Aug; 72(4):437-440. PubMed ID: 30140095
[TBL] [Abstract][Full Text] [Related]
47. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
[TBL] [Abstract][Full Text] [Related]
48. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
49. [Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results].
Molnár Z; Simon Z; Borbényi Z; Deák B; Galuska L; Keresztes K; Miltényi Z; Marton I; Rosta A; Schneider T; Trón L; Várady E; Illés A
Orv Hetil; 2009 Nov; 150(47):2133-8. PubMed ID: 19910278
[TBL] [Abstract][Full Text] [Related]
50. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen.
Picardi M; Soricelli A; Grimaldi F; Nicolai E; Gallamini A; Pane F
Ann Oncol; 2011 Mar; 22(3):671-680. PubMed ID: 20693297
[TBL] [Abstract][Full Text] [Related]
51. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
Terasawa T; Lau J; Bardet S; Couturier O; Hotta T; Hutchings M; Nihashi T; Nagai H
J Clin Oncol; 2009 Apr; 27(11):1906-14. PubMed ID: 19273713
[TBL] [Abstract][Full Text] [Related]
52. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
53. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans.
Picardi M; De Renzo A; Pane F; Nicolai E; Pacelli R; Salvatore M; Rotoli B
Leuk Lymphoma; 2007 Sep; 48(9):1721-7. PubMed ID: 17786707
[TBL] [Abstract][Full Text] [Related]
54. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
55. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
Cencini E; Fabbri A; Rigacci L; Lazzi S; Gini G; Cox MC; Mancuso S; Abruzzese E; Kovalchuk S; Goteri G; Di Napoli A; Bono R; Fratoni S; Di Lollo S; Bosi A; Leoncini L; Bocchia M
Hematol Oncol; 2017 Mar; 35(1):69-78. PubMed ID: 26251194
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
58.
Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
[TBL] [Abstract][Full Text] [Related]
59. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
60. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]